With shares of Corning (NYSE:GLW) trading around $17, is GLW an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.
T = Trends for a Stock’s MovementCorning produces and sells specialty glasses, ceramics, and related materials worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. Corning has launched Corning Lotus Glass, an environmentally friendly display glass for organic LED and LCD displays that are used in portable devices such as smartphones, tablets, and notebook computers. Smart phones, tablets, notebook computers, and their related materials are seeing explosive growth in developed and developing countries around the world.
Samsung Electronics���(SSNLF.PK)�purchase of Corning shares and a glass supply agreement between the two companies will last until 2023. Samsung Display is buying $2.3 billion worth of shares in Corning, according to a statement from Corning, making Samsung�� combined stake in Corning 7.4 percent. The Samsung purchase is expected to close in the first quarter of 2014.
Best Restaurant Companies To Watch For 2015: Catamaran Corp (CTRX)
Catamaran Corporation (Catamaran), formerly SXC Health Solutions Corp., incorporated on June 27, 2007, is a provider of pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefit management industry. The Company�� product offerings and solutions combine a range of applications and PBM services designed to assist its customers in reducing the cost and managing the complexity of their prescription drug programs. The Company�� customers include organizations in the pharmaceutical supply chain, such as pharmacy benefit managers, managed care organizations, self-insured employer groups, unions, third party health care plan administrators, and state and federal government entities. In January 2012, the Company completed its acquisition of HealthTran LLC (HealthTran). On July 2, 2012, the Company acquired Catalyst Health Solutions, Inc. On October 1, 2013, the Company acquired RESTAT, LLC.
The Company�� PBM services, which are marketed under the Catamaran PBM brand, include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services, data access, and reporting and information analysis. The Company's PBM services include owning and operating a network of mail and specialty pharmacies. In addition, the Company is a national provider of drug benefits to its customers under the federal government�� Medicare Part D program. The Company�� HCIT solutions include RxCLAIM, an on-line transaction processing system that provides instant adjudication of prescription drug claims, RxMAX, the Company�� rebate management system, RxTRACK, the Company�� data warehouse and analysis system, Zynchros, the Company�� suite of on-demand formulary management tools, the Company�� pharmacy management system! for retail, chain, institutional and mail-order pharmacies, as well as a number of other software products for customers in the pharmaceutical supply chain. The Company�� HCIT solutions are available on a license basis with on-going maintenance and support or on a transaction fee basis using an application service provider (ASP) model.
PBM Services
The Company�� informedRx offering is a suite of customizable PBM services that provide an alternative to traditional PBM offerings typically employed by health plans, government agencies and employers. The Company provides a range of pharmacy spend management solutions and information technology capabilities to managed care organizations, self-insured employer groups, unions, third party health care plan administrators, and state and federal government entities. Formulary Administration provides support for customers��existing formularies and preferred drug lists or collaborate to create models supported by formulary predictive modeling and impact analysis. Pharmacist, physician and member-focused intervention protocols provide controls to drive generics, preferred drug products and appropriate use. Formularies are administered based on specific plan designs, or by enabling customers with the tools to maintain their own custom formularies online.
The Company specializes in applying data-driven insights to help customers understand the medical risk drivers within their population and take a strategic approach to plan design. The Company provides benefit design configuration and support to customers, in accordance with mutually developed processes. Benefit designs can be modified online, in real time, by the Company or by the customer�� staff. Pharmacy Network Management provides a range of retail network options, including supporting existing networks or assisting customers in developing networks that meet specific geographic access requirements, desired price discounts, or other service requirements. A national! retail n! etwork, which consists of pharmacies in all 50 states and in Puerto Rico, Guam and the Virgin Islands, provides access to the Company�� customers.
Drug Utilization Review (DUR) is pre-dispensing DUR edit checks are performed on an online, real-time basis between mail and retail pharmacies to encourage appropriate drug utilization, enhance member outcomes, and reduce drug costs. All prescriptions are checked for member eligibility and plan design features and are then compared against previous histories of prescriptions filled by the same pharmacy, by other participating retail network pharmacies and by the mail service pharmacy. Clinical Services and Consulting provides consultative and technical expertise to augment, develop, deploy, and support any additional clinical programs. Reporting and Information Analysis Solutions provides two levels of reporting: a reporting package (which includes a menu of reports), and an online analytical decision support tool, RxTRACK. The Company offers mail and specialty services to its PBM members, as well as other members of its pharmacy network. suite of Web-based services that enables customers to interact with the claims processing system using a standardized protocol in a secure environment. A member Website, RxPORTAL, invites members to learn more about their prescription benefit programs, medication histories, drug information and related industry news. RxPROVIDER PORTAL is a Web-based interface that allows pharmacists and physicians to obtain information from RxCLAIM on a member's plan to assist in providing more cost effective prescription medications.
Healthcare IT
The Company's HCIT offerings deliver applications on a license, ASP, or fee-for-service basis to customers who administer and manage pharmacy benefits. HCIT products and services serve a diversified group of payor customers that include health plans, federal, state and provincial government programs, pharmacy benefit managers, workers' compensation programs! , and lon! g-term and/or chronic care facility operators. In addition, SXC's technology serves as the engine for the Company's service PBM solutions.
Technology Products and Services
RxCLAIM is an on-line transaction processing system designed to provide instant on-line adjudication of third-party prescription drug claims at the point of service, including claims management, as well as payment and billing support and real-time functionality for updating benefit, price, member, provider and drug details. RxCLAIM is designed to provide the Company�� customers control by facilitating the real-time processing of pharmacy claims and payments against eligibility, plan benefits, formularies, price, drug utilization review, prior authorization, and rebates in addition to many other features.
Other products
Integrail Pathfinder PRO is a software application that enables a array of users to understand the impact of healthcare resource allocation and medical decision-making through the incorporation of risk prediction and episode profiling technologies. The application offers users an intuitive system for integrating disparate data sources to pinpoint variations in resource utilization and care. IntegrailRx features the ability to measure and predict both pharmacy and total risk using pharmacy claims. RxBUILDER is a Web-based interface for formulary creation and maintenance utilizing a Medi-Span based product file. RxPORTAL allows customers to interact with the patient's formulary and drug history in a secure environment allowing patients and health plans to access industry tools and up to date information. RxAUTH is a prior authorization (PA) management solution, which offers automating the PA process from end-to-end. RxAUTH is also available in a Web-based application. RxMAX is a rebate management system that is designed to assist health plans in managing their relationships with pharmaceutical manufacturers through contract management, record keeping, calculating market share! , and cre! ating billing details and summaries. Zynchros provides a suite of on-demand formulary management tools to help payors effectively manage their formulary programs, and to maintain Medicare Part D compliance in their programs. Enhanced Coordination of Benefits integrates external data sources with unique algorithms and eligibility data to identify beneficiaries with other coverage. This enables accurate identification of third party liability in real-time prior to the claim being paid.
Medicare Part D
The Company has offered an array of services to the Medicare marketplace, all compliant with Centers for Medicare and Medicaid Services (CMS) regulations. As a full-service PBM and a National Prescription Drug Plan, the Company supports a variety of Medicare Part D Plan Sponsors. The Company provides prescription benefit management support for Medicare Advantage Prescription Drug plans (MAPDs) and prescription drug plans (PDPs), including implementation of specific Medicare Part D plan designs, creation and maintenance of Medicare Part D formularies (including CMS submission), CMS reporting requirements and consultative, proactive account management.
The Company competes with Express Scripts, Inc., CVS/Caremark Corporation and OptumRx.
Advisors' Opinion:- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care IT services specialist Catamaran (NASDAQ: CTRX ) has earned a respected four-star ranking. �
Top Life Sciences Companies To Own In Right Now: Spirit Realty Capital Inc (SRC)
Spirit Realty Capital, Inc., incorporated on August 14, 2003, is a self-administered and self-managed real estate investment trust (REIT). The Company�� operations are carried out through Spirit Realty, L.P. (the Operating Partnership). The Company invests in single-tenant, operationally essential real estate throughout the United States that is leased on a long-term, triple-net basis primarily to tenants engaged in retail, service and distribution industries. Single-tenant, operationally essential real estate consists of properties that are generally free-standing, commercial real estate facilities where its tenants conduct retail, service or distribution activities. as of December 31, 2012, the Company�� portfolio of 1,122 owned properties were leased to approximately 165 tenants. In July 2013, the Company merged with Cole Credit Property Trust II.
The Company�� tenants operate in 18 different industries, which include medical/other office properties; recreational properties; educational properties; automotive dealers, parts and services facilities; industrial properties; building material suppliers; movie theatres; restaurants-casual dining; specialty retail properties; restaurants-quick service, and general and discount retail properties. The Company�� properties are geographically diversified across 47 states, with only 4 states contributing more than 5.0% of its annual rent. As of December 31, 2012, approximately 98.0% of its lease and loan revenues were attributable to long-term leases. As of December 31, 2012, the Company leases 181 properties to Shopko/Pamida, 179 of which are leased pursuant to three master leases.
Advisors' Opinion:- [By Rich Duprey]
Commercial real estate investor�Spirit Realty Capital (NYSE: SRC ) announced today its second-quarter dividend of $0.3125�per share, the same rate it paid last quarter. After going public in September, it began making payouts to investors in January.
- [By Brad Thomas]
Finally, here's the report card. Agree has racked up a year-over-year total return of 43.19%. That's not bad, especially when you consider the noise generated by the big boys: Realty Income (O) 32.66%; National Retail Properties (NNN) 47.44%; W.P. Carey (WPC) 57.84%; Spirit Realty (SRC) 35.44%; and American Realty Capital Properties 52.18%.
- [By Rich Duprey]
With Spirit Realty Capital (NYSE: SRC ) set to merge with�Cole Credit Property Trust II in the third quarter, the commercial real estate REIT announced yesterday�it would pay a pro-rated dividend for the third quarter based on a quarterly payout of $0.3125 per share, the same rate it paid last quarter. Spirit only went public last September and began paying dividends in January.
- [By Brad Thomas]
Today, the public REIT markets are flowing strong as evidenced by a number of new mergers, rollups, listings, and IPOs. As I wrote in a previous article, Spirit Realty Capital (SRC) has announced its plan to acquire Cole Credit Property Trust II, Inc. (CCPT2) - a non-traded REIT with over 40,000 investors. With around 822 properties, CCPT2 will soon combine with Spirit (with a $1.82 billion market cap) to create a $7 billion enterprise with over 2,000 properties.
Top Life Sciences Companies To Own In Right Now: SPDR S&P Dividend ETF (SDY)
SPDR S&P Dividend ETF (the Fund) seeks to replicate the price and yield of the S&P High Yield Dividend Aristocrats Index (the Index). The Index is designed to measure the performance of 50 highest dividend yielding S&P Composite 1500 constituents that have followed a managed-dividends policy of consistently increasing dividends every year for at least 25 years. These stocks have both capital growth and dividend income characteristics.
The Fund utilizes a passive or indexing approach and attempts to approximate the investment performance of its benchmark index, by investing in a portfolio of stocks intended to replicate the Index. SSgA Funds Management, Inc. acts as the Adviser of the Fund.
Advisors' Opinion:- [By Dan Caplinger]
So if two single people each earned $200,000, they wouldn't be subject to the Obamacare tax at all. But if they got married, then $150,000 of their total income of $400,000 would get taxed, with an additional tax liability of $1,350. Similar situations with investment income could lead to a much larger marriage penalty, as the investment tax rate is more than quadruple the rate for wages.�Investors in dividend-oriented ETFs Vanguard High Dividend Yield (NYSEMKT: VYM ) , SPDR S&P Dividend (NYSEMKT: SDY ) , and iShares DJ Select Dividend (NYSEMKT: DVY ) should therefore take care to consider tax-favored investment vehicles for their investments.
Top Life Sciences Companies To Own In Right Now: Viacom Inc. (VIA)
Viacom Inc. operates as an entertainment content company in the United States and internationally. The company connects with audiences through compelling content on television, motion picture, online, and mobile platforms. It operates in two segments, Media Networks and Filmed Entertainment. The Media Networks segment provides entertainment content and related branded products to advertisers, content distributors, and retailers in various distribution platforms, such as television, online, and mobile devices, as well as through consumer products. It operates approximately 200 TV channels, and digital and mobile TV properties, which include MTV, VH1, CMT, Logo, BET, CENTRIC, Nickelodeon, Nick Jr., TeenNick, Nicktoons, Nick at Nite, COMEDY CENTRAL, TV Land, SPIKE, Tr3s, Paramount Channel, VIVA, and others, as well as a casual games business that includes Web sites, such as AddictingGames.com and Shockwave.com. In addition, this segment operates BET Networks, which provide en tertainment, music, news, and public affairs programming to the African-American audience; and BET channel, CENTRIC, BET Gospel, and BET Hip Hop, as well as BET.com, an online destination that offers content and interactive features for news, music, community, culture, and other areas to African-Americans. The Filmed Entertainment segment produces, finances, and distributes motion pictures and other entertainment content under the Paramount Pictures, Paramount Vantage, Paramount Classics, Insurge Pictures, MTV Films, and Nickelodeon Movies brands. It also acquires films for distribution, as well as distributes motion pictures and other entertainment content on DVD and Blu-ray, video-on-demand, subscription video-on-demand, pay and basic cable television, broadcast television, and syndicated television platforms. This segment has a library of approximately 3,300 motion pictures and television programs. The company is headquartered in New York, New York. Viacom, Inc. (NasdaqGS :VIAB) operates independently of CBS Corporation as of Dec! ember 31, 2005.
Advisors' Opinion:- [By Tim Beyers]
Viacom's (NASDAQ: VIA ) Paramount Pictures also has two summer hits on its hands. Star Trek Into Darkness recently topped $220 million at the U.S. box office and more than $438 million worldwide. Zombie thriller World War Z, meanwhile, has defied low expectations to earn an estimated $123 million in grosses through its second weekend, Box Office Mojo reports.
- [By Tim Beyers]
Pain and Gain from Viacom's (NASDAQ: VIA ) Paramount Studios ranked second, with $7.6 million at the gate, while 42 from Time Warner's (NYSE: TWX ) Warner Bros. studio earned $6.2 million, according to figures compiled by Box Office Mojo.
- [By WWW.DAILYFINANCE.COM]
Evan Agostini, Invision/APCBS president and CEO Leslie Moonves ranked No. 2 on a list of highest paid CEOs. LOS ANGELES -- Once again, media company CEOs are among the highest paid executives in the nation, occupying six of the top 10 earning spots, according to an Associated Press/Equilar study. Compensation experts say a variety of factors are at play, including the gain in media stocks, the intangible value of talent in a hit-or-miss business, the control of shareholder power in very few hands, and the decline of the financial sector. Stock Outperformers Outsized stock growth boosts the value of stock and option grants. Media companies' shares have rebounded strongly since the 2008 recession, mainly because advertising spending grows in tandem with a growing economy. That means higher-priced ads and higher-priced execs. Stocks of the six media companies on the list all outperformed the Standard & Poor's 500 index (^GPSC), which grew 128 percent in the five years through December 2013, according to FactSet. CBS (CBS) shares grew a whopping 699 percent in that period; Discovery Communications (DISCA) went up 539 percent; Viacom (VIA) rose 377 percent; Walt Disney (DIS) rose 250 percent; Time Warner (TWX) climbed 259 percent and Comcast (CMCSA) grew 223 percent. "If shareholders are happy they don't care how much a person makes," said Paul Dorf, managing director of consulting firm Compensation Resources. "When they complain most is when the market doesn't do well and their stock is going down the tubes." Talent Quotient Making it big in media means generating hits. And while top executives may not be hands-on with every decision, they are where the buck stops. Take Disney's animated blockbuster "Frozen," which grossed $1.2 billion at box offices worldwide. While Disney CEO Bob Iger didn't make the movie, he did orchestrate Disney's $7.4 billion acquisition of Pixar in 2006, which brought in talented executives to help reform Disney's faltering a
Top Life Sciences Companies To Own In Right Now: AutoCanada Inc (ACQ)
AutoCanada Inc. (AutoCanada) is a multi-location automobile dealership groups. As of December 31, 2011, the Company operated 24 franchised dealerships in British Columbia, Alberta, Manitoba, Ontario, New Brunswick and Nova Scotia. During the year ended December 31, 2011, its dealerships sold approximately 28,000 vehicles and processed approximately 300,000 service and collision repair orders in its 333 service bays. As of December 31, 2011, it was authorized to sell through its dealerships the vehicle brands, which include Chrysler, Dodge, Jeep, Ram, Fiat, Hyundai, Nissan, Infiniti, Volkswagen, Mitsubishi and Subaru. In addition, it sells a range of used vehicles. In November 2011, the Company acquired assets of two dealerships. In January 2013, the Company purchased the assets of a Volkswagen dealership known as People's Automotive Ltd. Advisors' Opinion:- [By Greg Quinn]
AutoCanada Inc. (ACQ), the country�� largest publicly traded chain of car dealerships, is using sales of trucks to Alberta oil workers to fund higher dividends and buy out competitors.
Top Life Sciences Companies To Own In Right Now: Agios Pharmaceuticals Inc (AGIO)
Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company�� ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (IEMs) are treated. The Company has identified and validated novel and druggable targets in both cancer and IEMs. The Company�� two advanced cancer programs are targeting mutations in the enzymes isocitrate dehydrogenase 1 and 2, referred to as IDH1 and IDH2. The Company�� drug candidates are selective for the mutated forms of IDH1 and IDH2 found in cancer cells versus the normal forms of IDH1 and IDH2 found in all other cells.
The Company focused on developing medicines to address IEMs, with a novel approach to these orphan diseases for which no effective or disease-modifying therapy is available. The Company has also de-validated and terminated numerous programs, including many that have been reported in scientific journals. In the Company�� IEM portfolio, it uses an equally rigorous set of validation techniques.
Advisors' Opinion:- [By Lisa Levin]
Agios Pharmaceuticals (NASDAQ: AGIO) shares touched a new 52-week low of $18.83. Agios Pharmaceuticals' trailing-twelve-month profit margin is -102.87%.
- [By Jake L'Ecuyer]
Shares of Agios Pharmaceuticals (NASDAQ: AGIO) got a boost, shooting up 29.08 percent to $40.84 after the company reported quarterly results.
Stage Stores (NYSE: SSI) was also up, gaining 13.47 percent to $22.41 after the company reported Q4 results and announced the sale of its Steele's off-price division to a new retail unit of Hilco Global.
- [By Roberto Pedone]
Another stock that insiders are moving into here is Agios Pharmaceuticals (AGIO), which focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism in the U.S. Insiders are buying this stock into major strength, since shares are up big so far in 2014 by 79%.
Agios Pharmaceuticals has a market cap of $1.4 billion and an enterprise value of $1.5 billion. This stock trades at a premium valuation, with a price-to-sales of 53.91 and a price-to-book of 11.51. Its estimated growth rate for this year is 48.1%, and for next year it's pegged at 15%. This is a cash-rich company, since the total cash position on its balance sheet is $162.27 million and its total debt is zero.
A director just bought 2,300 shares, or about $100,000 worth of stock, at $43.98 per share.
From a technical perspective, AGIO is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been selling off after a failed breakout attempt for the last few weeks, with shares moving lower from its high of $50.37 to its intraday low of $42.15 a share. That move is quickly pushing shares of AGIO within range of tagging its 50-day moving average of $40.27 a share.
If you're bullish on AGIO, then I would look for long-biased trades as long as this stock is trending above its 50-day at $40.27 and then once it breaks out above some near-term overhead resistance at $45 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 419,691 shares. If that breakout starts soon, then AGIO will set up to re-test or possibly take out its next major overhead resistance level at its all-time high of $50.37 a share. Any high-volume move above that level will then give AGIO a chance to tag $55 to $60 a share.
No comments:
Post a Comment